Oral Edaravone Dosing Timing for Meal-Dependent Absorption

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Edaravone, used as a therapeutic agent for ALS, is currently only available in injectable form and its oral administration is affected by meal types, leading to variations in pharmacokinetics.

Innovation Solution

Administering edaravone orally or intragastrically with specific time intervals after meals, such as 8 hours after a high-fat meal, 4 hours after a standard meal, or 2 hours after a light meal, to minimize meal effects on its pharmacokinetics.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If edaravone is administered orally, then the convenience of administration is improved, but the pharmacokinetic variability increases due to meal effects

Engineering Contradiction:

Improveadministration convenienceVSAvoidpharmacokinetic consistency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent changes the temporal parameter of administration by specifying precise time intervals after meals (8 hours for high-fat meals, 4 hours for standard meals, 2 hours for light meals). This parameter modification allows oral administration convenience while controlling pharmacokinetic variability through standardized timing protocols.

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If edaravone is administered immediately after meals, then patient compliance is improved, but drug absorption stability deteriorates

Engineering Contradiction:

Improvepatient complianceVSAvoiddrug absorption stability

Core Design Contradiction:

Adaptability or versatilityVSStability of the object's composition

Solution Approach 1:

The patent establishes preliminary action by pre-defining appropriate time intervals between meals and drug administration. These predetermined intervals (2-8 hours depending on meal type) are established before actual administration, allowing patients to maintain compliance while ensuring absorption stability through advance planning of administration timing.

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If edaravone formulation is changed to oral, then treatment accessibility is improved, but pharmacokinetic control becomes more difficult

Engineering Contradiction:

Improvetreatment accessibilityVSAvoidpharmacokinetic control complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent simplifies pharmacokinetic control by changing the timing parameter to specific intervals after meals rather than requiring complex dosing schedules. This parameter modification makes the formulation easier to control while maintaining treatment accessibility through oral administration.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12569469B2Pharmaceutical composition for oral administration of edaravone and method of administering same

Publication Date: 2026.03.10 SHIONOGI INC

AI summary

A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.